FY2025 EPS Estimate for ProAssurance Increased by Analyst

Key Points

• Zacks Research has raised its FY2025 earnings per share estimate for ProAssurance to $1.18, reflecting increased confidence in the company's performance, while the consensus estimate for FY2024 remains at $0.80 per share.
• In its recent quarterly report, ProAssurance exceeded earnings expectations with $0.52 EPS for Q2 2025, significantly above the consensus estimate of $0.19, despite a revenue decline of 19.9% year-over-year.
• Significant institutional interest in ProAssurance is evident as various large investors have increased their stakes, bringing institutional ownership to 85.58% of the company’s shares.

ProAssurance Corporation (NYSE:PRA - Free Report) - Equities researchers at Zacks Research raised their FY2025 earnings per share estimates for ProAssurance in a note issued to investors on Tuesday, September 23rd. Zacks Research analyst Team now expects that the insurance provider will earn $1.18 per share for the year, up from their previous forecast of $1.17. Zacks Research has a "Strong-Buy" rating on the stock. The consensus estimate for ProAssurance's current full-year earnings is $0.80 per share. Zacks Research also issued estimates for ProAssurance's Q2 2026 earnings at $0.28 EPS, FY2026 earnings at $1.07 EPS and FY2027 earnings at $1.26 EPS.

ProAssurance (NYSE:PRA - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The insurance provider reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.33. The firm had revenue of $271.94 million for the quarter, compared to analyst estimates of $266.72 million. ProAssurance had a return on equity of 5.62% and a net margin of 4.33%.The business's revenue for the quarter was down 19.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.23 earnings per share.

ProAssurance Price Performance

NYSE:PRA opened at $23.87 on Wednesday. The company has a quick ratio of 0.26, a current ratio of 0.26 and a debt-to-equity ratio of 0.33. The stock's 50 day moving average price is $23.83 and its two-hundred day moving average price is $22.97. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of 25.39 and a beta of 0.12. ProAssurance has a 12-month low of $13.00 and a 12-month high of $24.14.

Hedge Funds Weigh In On ProAssurance

Large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. increased its stake in shares of ProAssurance by 356.2% during the second quarter. Russell Investments Group Ltd. now owns 1,405 shares of the insurance provider's stock worth $32,000 after purchasing an additional 1,097 shares during the period. Quantbot Technologies LP bought a new position in shares of ProAssurance during the first quarter worth approximately $47,000. GAMMA Investing LLC increased its stake in shares of ProAssurance by 307.3% during the first quarter. GAMMA Investing LLC now owns 2,073 shares of the insurance provider's stock worth $48,000 after purchasing an additional 1,564 shares during the period. CWM LLC increased its stake in shares of ProAssurance by 95.9% during the first quarter. CWM LLC now owns 2,204 shares of the insurance provider's stock worth $51,000 after purchasing an additional 1,079 shares during the period. Finally, Longfellow Investment Management Co. LLC bought a new position in shares of ProAssurance during the first quarter worth approximately $75,000. Institutional investors own 85.58% of the company's stock.

About ProAssurance

ProAssurance Corporation, through its subsidiaries, provides property and casualty insurance, and reinsurance products in the United States. The company operates through Specialty Property and Casualty, Workers' Compensation Insurance, and Segregated Portfolio Cell Reinsurance segments. It offers professional liability insurance to healthcare providers and institutions, and attorneys and their firms; medical technology liability insurance to medical technology and life sciences companies; and custom alternative risk solutions, including assumed reinsurance, loss portfolio transfers, and captive cell programs for healthcare professional liability insureds.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.